middle.news
Dimerix Advances to 70% Recruitment in Pivotal FSGS Trial
9:09am on Friday 13th of June, 2025 AEST
•
Healthcare
Read Story
Dimerix Advances to 70% Recruitment in Pivotal FSGS Trial
9:09am on Friday 13th of June, 2025 AEST
Key Points
200 of 286 adult patients dosed, representing 70% trial completion
Recruitment on track to finish in second half of 2025
Trial spans over 190 sites across 22 countries
Six safety reviews passed by Independent Data Monitoring Committee
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Dimerix (ASX:DXB)
OPEN ARTICLE